← Eichor
Study identifier: NCT07252739 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Condition: Malignant Neoplasm  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 2
Planned participants130
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (34)

Clermont Oncology Center ( Site 0041)Clermont, Florida, United StatesRecruiting
Sanford Health Roger Maris Cancer Center ( Site 0039)Fargo, North Dakota, United StatesRecruiting
Sanford Cancer Center Oncology Clinic ( Site 0038)Sioux Falls, South Dakota, United StatesRecruiting
Fundacion Arturo Lopez Perez ( Site 0167)Santiago, Region M. de Santiago, ChileRecruiting
Centro de Oncología de Precisión ( Site 0160)Santiago, Region M. de Santiago, ChileRecruiting
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)Nanjing, Jiangsu, ChinaRecruiting
West China Hospital, Sichuan University ( Site 0315)Chengdu, Sichuan, ChinaRecruiting
Kuopion Yliopistollinen Sairaala ( Site 0261)Kuopio, Northern Savonia, FinlandRecruiting
Vaasan Keskussairaala ( Site 0263)Vaasa, Pohjanmaa, FinlandRecruiting
Turku University Hospital ( Site 0262)Turku, Southwest Finland, FinlandRecruiting
HYKS Syöpätautien klinikka ( Site 0260)Helsinki, Uusimaa, FinlandRecruiting
Hong Kong Integrated Oncology Centre ( Site 0232)Central, Hong KongRecruiting

+ 22 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07252739